Clarivate Plc Stock Price, News & Analysis

Clarivate Plc (CLVT) released a report highlighting that innovation in sustainable energy is declining, particularly in solar and wind power, which are nearing technical maturity. Although these energies have seen significant research over the last three decades, the report suggests that activity is slowing down. Oceanic power is still developing, showing potential but currently lacking maturity.

China leads in renewable energy innovation, outpacing the U.S. in patent activity. The study provides insights into research gaps and trends, aligning with global sustainability goals.

Clarivate Plc (NYSE:CLVT) has released a report titled RNA Technology Companies to Watch, highlighting seven innovative companies in the RNA technology space. These firms are addressing undruggable disease targets, demonstrating potential benefits such as fewer side effects and enhanced efficacy. The report notes a significant increase in RNA-related scientific research and patent filings, with the U.S. and Mainland China leading advancements. Despite challenges in RNA stability and delivery, the sector remains promising.

Clarivate Plc (NYSE:CLVT) published a report analyzing formal regional research assessment systems across Australia, Canada, Germany, Hong Kong, New Zealand, and the UK. The report indicates improvements in comparative research performance but lacks a consensus on whether research assessment is essential. Key insights include Australia's unique methodology, Canada's focus on knowledge mobilization, and the UK's historical role in establishing research assessment models. The report also highlights potential biases in AI-driven assessments and their implications for the research ecosystem.

On Sept. 28, 2022, Clarivate Plc (NYSE: CLVT) announced it will report its third quarter 2022 financial results on November 8, 2022, before market opening. A conference call at 9:00 AM ET will follow for discussion on the results, accessible via the investor relations website. Additionally, the company is planning an Investor Day in the first quarter of 2023 post the fourth quarter results in February, where executives will update on strategy and fiscal 2023 guidance, alongside product demonstrations.

On September 22, 2022, Clarivate Plc (NYSE: CLVT) announced the launch of upgraded Web of Science™ Researcher Profiles, enhancing services for researchers by consolidating their academic publications, citation metrics, and peer review activities. This initiative, celebrated during Peer Review Week, aims to provide recognition for peer reviewers and support scholars in managing their contributions efficiently. Notably, researcher profile page views surged by nearly 320%, underlining the growing visibility of academic work. The upgraded platform offers various features to help researchers showcase their expertise and keep track of citation impacts.

On September 21, 2022, Clarivate Plc (NYSE: CLVT) announced its 2022 Citation Laureates, honoring 20 researchers whose work is recognized as 'of Nobel class'. The selection process utilized data from Web of Science, identifying highly cited publications out of more than 55 million indexed articles. Notable honorees include Masato Hasegawa, Virginia Man-Yee Lee, and Stephen R. Quake among others. Clarivate noted that 64 previous Citation Laureates have received Nobel Prizes, emphasizing the credibility of their research contributions.

Clarivate Plc (NYSE:CLVT) has announced the full migration of BioWorld Science to bioworld.com, completing the brand consolidation of its news portfolio. This transition enhances user experience with expanded news coverage and intuitive navigation. The new platform will provide readers daily access to comprehensive drug R&D news, including exclusive insights and in-depth articles, along with improved functionalities such as a daily newsletter. BioWorld aims to support critical decision-making in drug development by delivering timely and relevant information.

Clarivate has entered into an agreement with Newfold Digital for the sale of MarkMonitor, an enterprise-level domain management provider, for approximately $302.5 million. The transaction is expected to finalize in late 2022, pending regulatory approvals. MarkMonitor is projected to generate $80 million in revenue and $35 million in EBITDA for 2022. This acquisition will enhance Newfold's domain management solutions, benefiting its extensive customer base, including Fortune 500 companies, and allow Clarivate to concentrate on its core IP management portfolio.